EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)

Naim Shehadeh, Pietro Galassetti, Nayyar Iqbal, Cecilia Karlsson iD, John Monyak, Jennifer Ostridge, Marie Bolin, Timothy Barrett iD

The Journal of Clinical Endocrinology & Metabolism · 19.05.2025 · 110 (6) · 1587-1595

DOI: 10.1210/clinem/dgae723 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 24.10.2024. Verfasst von Naim Shehadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptides, Glucosides, Adamantane. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The T2NOW trial of dapagliflozin or saxagliptin vs placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety concerns over 52 weeks.

Objective

This work aimed to assess long-term effects of prior dapagliflozin/saxagliptin administration on safety, growth, and development.

Methods

A multicenter, randomized, double-blind phase 3 trial (T2NOW) was conducted among 210 children with T2D aged 10 to 17 years, followed for up to 1 year after treatment. Participants were previously treated with once-daily dapagliflozin (5, 10 mg), saxagliptin (2.5, 5 mg), or placebo as an add-on to diet, exercise, metformin, and/or insulin for 52 weeks, plus a 52-week nontreatment follow-up period. Main outcome measures included change in height, weight, body mass index (BMI), Tanner staging, growth and maturation markers, bone biomarkers, and adverse events (AEs) from baseline to week 104.

Results

As expected in a pediatric population, mean height and weight slightly increased from baseline to week 104. BMI remained generally stable; changes were similar across treatment groups. Sexual maturation progressed normally to week 104, with similar shifts between Tanner stages and changes in growth and maturation markers and bone biomarkers across groups. The proportion of patients reporting 1 or more AEs during the nontreatment follow-up period was similar across groups previously treated with dapagliflozin (18.5%) or saxagliptin (15.9%) compared to placebo (21.1%). No deaths occurred.

Conclusion

Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks following treatment discontinuation in pediatric patients with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2DipeptidesGlucosidesAdamantaneBenzhydryl CompoundsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsHumansChildAdolescentFemaleMaleDouble-Blind MethodFollow-Up StudiesBody HeightBody WeightBody Mass IndexTreatment OutcomeDipeptidyl-Peptidase IV Inhibitors

Stichwörter der Autor:innen

DPP4 inhibitorSGLT2 inhibitordapagliflozinpediatricsaxagliptintype 2 diabetes

Substanzen

saxagliptindapagliflozinDipeptidesGlucosidesAdamantaneBenzhydryl CompoundsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, 1311502, Israel.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 43183, Sweden.
  • Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.

ORCID-Profile: Cecilia Karlsson, Timothy Barrett

Förderung

  • AstraZeneca

Zitieren

APA

Shehadeh, N., Galassetti, P., Iqbal, N., Karlsson, C., Monyak, J., Ostridge, J., Bolin, M., & Barrett, T. (2025). Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up). The Journal of Clinical Endocrinology & Metabolism, 110(6), 1587-1595. https://doi.org/10.1210/clinem/dgae723

Vancouver

Shehadeh N, Galassetti P, Iqbal N, Karlsson C, Monyak J, Ostridge J, et al. Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up). The Journal of Clinical Endocrinology & Metabolism. 2025;110(6):1587-1595. doi:10.1210/clinem/dgae723

BibTeX
@article{Shehadeh2025,
  author = {Shehadeh, Naim and Galassetti, Pietro and Iqbal, Nayyar and Karlsson, Cecilia and Monyak, John and Ostridge, Jennifer and Bolin, Marie and Barrett, Timothy},
  title = {Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {6},
  pages = {1587--1595},
  doi = {10.1210/clinem/dgae723}
}
Kostenlos starten →